The development of an AIDS mucosal vaccine

Viruses

Volumn 2, Issue 1, 2010, Pages 283-297

  Tang, Xian ^a   Chen, Zhiwei ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Aids; Hiv 1; Mucosal vaccination; Mvtt; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; VACCINIA VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; CD8+ T LYMPHOCYTE; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; GENE EXPRESSION REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFLUENZA; MUCOSA; MUCOSAL IMMUNITY; NONHUMAN; REVIEW; SALMONELLA ENTERICA; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TYPE III SECRETION SYSTEM; UPREGULATION; VACCINATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; VARIOLA VIRUS;

EID: 79952083300     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2010283     Document Type: Review

References (82)

1. Holmgren, J.; Czerkinsky, C.; Lycke, N.; Svennerholm, A.M. Mucosal immunity: implications for vaccine development. Immunobiology 1992, 184, 157-179.
2. Schneider, T.; Ullrich, R.; Zeitz, M. [Gastrointestinal manifestations of HIV infection.] Zeitschrift fuer Gastroenterologie 1994, 32, 174-181.
3. Holmgren, J.; Czerkinsky, C. Mucosal immunity and vaccines. Nat. Med. 2005, 11, S45-S53.
4. Mestecky, J.; Mucosal Immunology, 3rd ed.; Elsevier Academic Press: Burlington, MA, USA, 2005; pp 372.
5. Brandtzaeg, P. Review article: Homing of mucosal immune cells--a possible connection between intestinal and articular inflammation. Aliment. Pharmacol. Ther. 1997, 11 (Suppl. 3), 24-37; discussion 37-39.
6. Kunkel, E.J.; Butcher, E.C. Plasma-cell homing. Nat. Rev. Immunol. 2003, 3, 822-829.
7. Paul, W.E. Fundamental Immunology. 5th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA; London, UK, 2003; pp. 23-46.
8. Paul, W.E. Fundamental Immunology. 6th ed.; Wolters Kluwer/Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2008; pp. 1236.
9. Sabin, A.B.; Ramos-Alvarez, M.; Alvarez-Amezquita, J.; Pelon, W.; Michaels, R.H.; Spigland, I.; Koch, M.A.; Barnes, J.M.; Rhim, J.S. Live, orally given poliovirus vaccine. Effects of rapid mass immunization on population under conditions of massive enteric infection with other viruses. JAMA 1960, 173, 1521-1526.
10. Jin, H.; Lu, B.; Zhou, H.; Ma, C.; Zhao, J.; Yang, C.F.; Kemble, G.; Greenberg, H. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 2003, 306, 18-24.
11. Buonagurio, D.A.; Bechert, T.M.; Yang, C.F.; Shutyak, L.; D'Arco, G.A.; Kazachkov, Y.; Wang, H.P.; Rojas, E.A.; O'Neill, R.E.; Spaete, R.R.; Coelingh, K.L.; Zamb, T.J.; Sidhu, M.S.; Udem, S.A. Genetic stability of live, cold-adapted influenza virus components of the FluMist/CAIV-T vaccine throughout the manufacturing process. Vaccine 2006, 24, 2151-2160.
12. Harper, S.A.; Fukuda, K.; Cox, N.J.; Bridges, C.B. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2003, 52, 1-8.
13. Zhang, L.; He, T.; Huang, Y.; Chen, Z.; Guo, Y.; Wu, S.; Kunstman, K.J.; Brown, R.C.; Phair, J.P.; Neumann, A.U.; Ho, D.D.; Wolinsky, S.M. Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J. Virol. 1998, 72, 9307-9312.
14. Chen, Z.; Zhou, P.; Ho, D.D.; Landau, N.R.; Marx, P.A. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J. Virol. 1997, 71, 2705-2714.
15. Veazey, R.; Lackner, A. The mucosal immune system and HIV-1 infection. AIDS Rev 2003, 5, 245-252.
16. Li, Q.; Skinner, P.J.; Ha, S.J.; Duan, L.; Mattila, T.L.; Hage, A.; White, C.; Barber, D.L.; O'Mara, L.; Southern, P.J.; Reilly, C.S.; Carlis, J.V.; Miller, C.J.; Ahmed, R.; Haase, A.T. Visualizing antigen-specific and infected cells in situ predicts outcomes in early viral infection. Science 2009, 323, 1726-1729.
17. Veazey, R.S.; DeMaria, M.; Chalifoux, L.V.; Shvetz, D.E.; Pauley, D.R.; Knight, H.L.; Rosenzweig, M.; Johnson, R.P.; Desrosiers, R.C.; Lackner, A.A. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998, 280, 427-431.
18. Lackner, A.A.; Mohan, M.; Veazey, R.S. The gastrointestinal tract and AIDS pathogenesis. Gastroenterology 2009, 136, 1965-1978.
19. Harouse, J.M.; Gettie, A.; Tan, R.C.; Blanchard, J.; Cheng-Mayer, C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999, 284, 816-819.
20. Chen, Z.; Zhao, X.; Huang, Y.; Gettie, A.; Ba, L.; Blanchard, J.; Ho, D.D. CD4+ lymphocytopenia in acute infection of Asian macaques by a vaginally transmissible subtype-C, CCR5-tropic Simian/Human Immunodeficiency Virus (SHIV). J. Acquir. Immune Defic. Syndr. 2002, 30, 133-145.
21. Brenchley, J.M.; Schacker, T.W.; Ruff, L.E.; Price, D.A.; Taylor, J.H.; Beilman, G.J.; Nguyen, P.L.; Khoruts, A.; Larson, M.; Haase, A.T.; Douek, D.C. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 2004, 200, 749-759.
22. Mehandru, S.; Poles, M.A.; Tenner-Racz, K.; Horowitz, A.; Hurley, A.; Hogan, C.; Boden, D.; Racz, P.; Markowitz, M. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J. Exp. Med. 2004, 200, 761-770.
23. Zhang, Z.; Schuler, T.; Zupancic, M.; Wietgrefe, S.; Staskus, K.A.; Reimann, K.A.; Reinhart, T.A.; Rogan, M.; Cavert, W.; Miller, C.J.; Veazey, R.S.; Notermans, D.; Little, S.; Danner, S.A.; Richman, D.D.; Havlir, D.; Wong, J.; Jordan, H.L.; Schacker, T.W.; Racz, P.; Tenner-Racz, K.; Letvin, N.L.; Wolinsky, S.; Haase, A.T. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells. Science 1999, 286, 1353-1357.
24. Spira, A.I.; Marx, P.A.; Patterson, B.K.; Mahoney, J.; Koup, R.A.; Wolinsky, S.M.; Ho, D.D. Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J. Exp. Med. 1996, 183, 215-225.
25. Smith, S.M.; Baskin, G.B.; Marx, P.A. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J. Infect. Dis. 2000, 182, 708-715.
26. Miller, C.J.; Li, Q.; Abel, K.; Kim, E.Y.; Ma, Z.M.; Wietgrefe, S.; La Franco-Scheuch, L.; Compton, L.; Duan, L.; Shore, M.D.; Zupancic, M.; Busch, M.; Carlis, J.; Wolinsky, S.; Haase, A.T. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J. Virol. 2005, 79, 9217-9127.
27. Salazar-Gonzalez, J.F.; Salazar, M.G.; Keele, B.F.; Learn, G.H.; Giorgi, E.E.; Li, H.; Decker, J.M.; Wang, S.; Baalwa, J.; Kraus, M.H.; Parrish, N.F.; Shaw, K.S.; Guffey, M.B.; Bar, K.J.; Davis, K.L.; Ochsenbauer-Jambor, C.; Kappes, J.C.; Saag, M.S.; Cohen, M.S.; Mulenga, J.; Derdeyn, C.A.; Allen, S.; Hunter, E.; Markowitz, M.; Hraber, P.; Perelson, A.S.; Bhattacharya, T.; Haynes, B.F.; Korber, B.T.; Hahn, B.H.; Shaw, G.M. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 2009, 206, 1273-1289.
28. Keele, B.F.; Giorgi, E.E.; Salazar-Gonzalez, J.F.; Decker, J.M.; Pham, K.T.; Salazar, M.G.; Sun, C.; Grayson, T.; Wang, S.; Li, H.; Wei, X.; Jiang, C.; Kirchherr, J.L.; Gao, F.; Anderson, J.A.; Ping, L.H.; Swanstrom, R.; Tomaras, G.D.; Blattner, W.A.; Goepfert, P.A.; Kilby, J.M.; Saag, M.S.; Delwart, E.L.; Busch, M.P.; Cohen, M.S.; Montefiori, D.C.; Haynes, B.F.; Gaschen, B.; Athreya, G.S.; Lee, H.Y.; Wood, N.; Seoighe, C.; Perelson, A.S.; Bhattacharya, T.; Korber, B.T.; Hahn, B.H.; Shaw, G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 2008, 105, 7552-7557.
29. Mattapallil, J.J.; Douek, D.C.; Hill, B.; Nishimura, Y.; Martin, M.; Roederer, M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005, 434, 1093-1097.
30. Li, Q.; Duan, L.; Estes, J.D.; Ma, Z.M.; Rourke, T.; Wang, Y.; Reilly, C.; Carlis, J.; Miller, C.J.; Haase, A.T. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005, 434, 1148-1152.
31. Alexander, R.; Mestecky, J. Neutralizing antibodies in mucosal secretions: IgG or IgA? Curr. HIV Res. 2007, 5, 588-593.
32. Devito, C.; Hinkula, J.; Kaul, R.; Lopalco, L.; Bwayo, J.J.; Plummer, F.; Clerici, M.; Broliden, K. Mucosal and plasma IgA from HIV-exposed seronegative individuals neutralize a primary HIV-1 isolate. Aids 2000, 14, 1917-1920.
33. Devito, C.; Hinkula, J.; Kaul, R.; Kimani, J.; Kiama, P.; Lopalco, L.; Barass, C.; Piconi, S.; Trabattoni, D.; Bwayo, J.J.; Plummer, F.; Clerici, M.; Broliden, K. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. J. Acquir. Immune Defic. Syndr. 2002, 30, 413-420.
34. Broliden, K.; Hinkula, J.; Devito, C.; Kiama, P.; Kimani, J.; Trabbatoni, D.; Bwayo, J.J.; Clerici, M.; Plummer, F.; Kaul, R. Functional HIV-1 specific IgA antibodies in HIV-1 exposed, persistently IgG seronegative female sex workers. Immunol. Lett. 2001, 79, 29-36.
35. Tudor, D.; Derrien, M.; Diomede, L.; Drillet, A.S.; Houimel, M.; Moog, C.; Reynes, J.M.; Lopalco, L.; Bomsel, M. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2009, 2, 412-426.
36. Dorrell, L.; Hessell, A.J.; Wang, M.; Whittle, H.; Sabally, S.; Rowland-Jones, S.; Burton, D.R.; Parren, P.W. Absence of specific mucosal antibody responses in HIV-exposed uninfected sex workers from the Gambia. Aids 2000, 14, 1117-1122.
37. Schneider, J.A.; Alam, S.A.; Ackers, M.; Parekh, B.; Chen, H.Y.; Graham, P.; Gurwith, M.; Mayer, K.; Novak, R.M. Mucosal HIV-binding antibody and neutralizing activity in high-risk HIV-uninfected female participants in a trial of HIV-vaccine efficacy. J. Infect. Dis. 2007, 196, 1637-1644.
38. Pastori, C.; Weiser, B.; Barassi, C.; Uberti-Foppa, C.; Ghezzi, S.; Longhi, R.; Calori, G.; Burger, H.; Kemal, K.; Poli, G.; Lazzarin, A.; Lopalco, L. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood 2006, 107, 4825-4833.
39. Renegar, K.B.; Small, P.A., Jr.; Boykins, L.G.; Wright, P.F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J. Immunol. 2004, 173, 1978-1986.
40. Wolbank, S.; Kunert, R.; Stiegler, G.; Katinger, H. Characterization of human class-switched polymeric (immunoglobulin M [IgM] and IgA) anti-human immunodeficiency virus type 1 antibodies 2F5 and 2G12. J. Virol. 2003, 77, 4095-40103.
41. Hessell, A.J.; Poignard, P.; Hunter, M.; Hangartner, L.; Tehrani, D.M.; Bleeker, W.K.; Parren, P.W.; Marx, P.A.; Burton, D.R. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 2009, 15, 951-954.
42. Hessell, A.J.; Rakasz, E.G.; Poignard, P.; Hangartner, L.; Landucci, G.; Forthal, D.N.; Koff, W.C.; Watkins, D.I.; Burton, D.R. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009, 5, e1000433:1-e1000433:9.
43. Jin, X.; Bauer, D.E.; Tuttleton, S.E.; Lewin, S.; Gettie, A.; Blanchard, J.; Irwin, C.E.; Safrit, J.T.; Mittler, J.; Weinberger, L.; Kostrikis, L.G.; Zhang, L.; Perelson, A.S.; Ho, D.D. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189, 991-998.
44. Schmitz, J.E.; Kuroda, M.J.; Santra, S.; Sasseville, V.G.; Simon, M.A.; Lifton, M.A.; Racz, P.; Tenner-Racz, K.; Dalesandro, M.; Scallon, B.J.; Ghrayeb, J.; Forman, M.A.; Montefiori, D.C.; Rieber, E.P.; Letvin, N.L.; Reimann, K.A. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283, 857-860.
45. Goonetilleke, N.; Liu, M.K.; Salazar-Gonzalez, J.F.; Ferrari, G.; Giorgi, E.; Ganusov, V.V.; Keele, B.F.; Learn, G.H.; Turnbull, E.L.; Salazar, M.G.; Weinhold, K.J.; Moore, S.; Letvin, N.; Haynes, B.F.; Cohen, M.S.; Hraber, P.; Bhattacharya, T.; Borrow, P.; Perelson, A.S.; Hahn, B.H.; Shaw, G.M.; Korber, B.T.; McMichael, A.J. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 2009, 206, 1253-1272.
46. Vogel, T.U.; Reynolds, M.R.; Fuller, D.H.; Vielhuber, K.; Shipley, T.; Fuller, J.T.; Kunstman, K.J.; Sutter, G.; Marthas, M.L.; Erfle, V.; Wolinsky, S.M.; Wang, C.; Allison, D.B.; Rud, E.W.; Wilson, N.; Montefiori, D.; Altman, J.D.; Watkins, D.I. Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J. Virol. 2003, 77, 13348-13360.
47. Evans, D.T.; Chen, L.M.; Gillis, J.; Lin, K.C.; Harty, B.; Mazzara, G.P.; Donis, R.O.; Mansfield, K.G.; Lifson, J.D.; Desrosiers, R.C.; Galan, J.E.; Johnson, R.P. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J. Virol. 2003, 77, 2400-2409.
48. Baig, J.; Levy, D.B.; McKay, P.F.; Schmitz, J.E.; Santra, S.; Subbramanian, R.A.; Kuroda, M.J.; Lifton, M.A.; Gorgone, D.A.; Wyatt, L.S.; Moss, B.; Huang, Y.; Chakrabarti, B.K.; Xu, L.; Kong, W.P.; Yang, Z.Y.; Mascola, J.R.; Nabel, G.J.; Carville, A.; Lackner, A.A.; Veazey, R.S.; Letvin, N.L. Elicitation of simian immunodeficiency virus-specific cytotoxic T lymphocytes in mucosal compartments of rhesus monkeys by systemic vaccination. J. Virol. 2002, 76, 11484-11490.
49. Stevceva, L.; Alvarez, X.; Lackner, A.A.; Tryniszewska, E.; Kelsall, B.; Nacsa, J.; Tartaglia, J.; Strober, W.; Franchini, G. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. J. Virol. 2002, 76, 11659-11676.
50. Kaul, R.; Plummer, F.A.; Kimani, J.; Dong, T.; Kiama, P.; Rostron, T.; Njagi, E.; MacDonald, K.S.; Bwayo, J.J.; McMichael, A.J.; Rowland-Jones, S.L. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J. Immunol. 2000, 164, 1602-1611.
51. Ibarrondo, F.J.; Anton, P.A.; Fuerst, M.; Ng, H.L.; Wong, J.T.; Matud, J.; Elliott, J.; Shih, R.; Hausner, M.A.; Price, C.; Hultin, L.E.; Hultin, P.M.; Jamieson, B.D.; Yang, O.O. Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J. Virol. 2005, 79, 4289-4297.
52. Bourinbaiar, A.S.; Metadilogkul, O.; Jirathitikal, V. Mucosal AIDS vaccines. Viral Immunol. 2003, 16, 427-445.
53. Jiang, J.Q.; Patrick, A.; Moss, R.B.; Rosenthal, K.L. CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides. J. Virol. 2005, 79, 393-400.
54. Walker, R.I. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994, 12, 387-400.
55. Kyd, J.M.; Cripps, A.W. Killed whole bacterial cells, a mucosal delivery system for the induction of immunity in the respiratory tract and middle ear: an overview. Vaccine 1999, 17, 1775-1781.
56. Kyd, J.; Cripps, A. Identifying vaccine antigens and assessing delivery systems for the prevention of bacterial infections. J. Biotechnol. 2000, 83, 85-90.
57. Cripps, A.W.; Kyd, J.M.; Foxwell, A.R. Vaccines and mucosal immunisation. Vaccine 2001, 19, 2513-2515.
58. Nilsson, C.; Makitalo, B.; Thorstensson, R.; Norley, S.; Binninger-Schinzel, D.; Cranage, M.; Rud, E.; Biberfeld, G.; Putkonen, P. Live attenuated simian immunodeficiency virus (SIV)mac in macaques can induce protection against mucosal infection with SIVsm. AIDS (London, England) 1998, 12, 2261-2270.
59. Cromwell, M.A.; Veazey, R.S.; Altman, J.D.; Mansfield, K.G.; Glickman, R.; Allen, T.M.; Watkins, D.I.; Lackner, A.A.; Johnson, R.P. Induction of mucosal homing virus-specific CD8(+) T lymphocytes by attenuated simian immunodeficiency virus. J. Virol. 2000, 74, 8762-8766.
60. Tenner-Racz, K.; Stahl Hennig, C.; Uberla, K.; Stoiber, H.; Ignatius, R.; Heeney, J.; Steinman, R.M.; Racz, P. Early protection against pathogenic virus infection at a mucosal challenge site after vaccination with attenuated simian immunodeficiency virus. Proc. Natl. Acad. Sci. USA 2004, 101, 3017-3022.
61. Kent, S.J.; Dale, C.J.; Ranasinghe, C.; Stratov, I.; De Rose, R.; Chea, S.; Montefiori, D.C.; Thomson, S.; Ramshaw, I.A.; Coupar, B.E.; Boyle, D.B.; Law, M.; Wilson, K.M.; Ramsay, A.J. Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3. Vaccine 2005, 23, 5009-5021.
62. Gherardi, M.M.; Perez-Jimenez, E.; Najera, J.L.; Esteban, M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modified vaccinia virus Ankara boost immunization schedule. J. Immunol. 2004, 172, 6209-6220.
63. Wang, S.W.; Bertley, F.M.; Kozlowski, P.A.; Herrmann, L.; Manson, K.; Mazzara, G.; Piatak, M.; Johnson, R.P.; Carville, A.; Mansfield, K.; Aldovini, A. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res. Hum. Retroviruses 2004, 20, 846-859.
64. Chen, Z.; Zhang, L.; Qin, C.; Ba, L.; Yi, C.E.; Zhang, F.; Wei, Q.; He, T.; Yu, W.; Yu, J.; Gao, H.; Tu, X.; Gettie, A.; Farzan, M.; Yuen, K.Y.; Ho, D.D. Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region. J. Virol. 2005, 79, 2678-2688.
65. Bisht, H.; Roberts, A.; Vogel, L.; Bukreyev, A.; Collins, P.L.; Murphy, B.R.; Subbarao, K.; Moss, B. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. USA 2004, 101, 6641-6646.
66. Degano, P.; Schneider, J.; Hannan, C.M.; Gilbert, S.C.; Hill, A.V. Gene gun intradermal DNA immunization followed by boosting with modified vaccinia virus Ankara: enhanced CD8+ T cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 1999, 18, 623-632.
67. Sutter, G.; Wyatt, L.S.; Foley, P.L.; Bennink, J.R.; Moss, B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 1994, 12, 1032-1040.
68. Olszewska, W.; Suezer, Y.; Sutter, G.; Openshaw, P.J. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 2004, 23, 215-221.
69. de Waal, L.; Wyatt, L.S.; Yuksel, S.; van Amerongen, G.; Moss, B.; Niesters, H.G.; Osterhaus, A.D.; de Swart, R.L. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine 2004, 22, 923-926.
70. Wyatt, L.S.; Whitehead, S.S.; Venanzi, K.A.; Murphy, B.R.; Moss, B. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine 1999, 18, 392-397.
71. Staats, H.F.; Bradney, C.P.; Gwinn, W.M.; Jackson, S.S.; Sempowski, G.D.; Liao, H.X.; Letvin, N.L.; Haynes, B.F. Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. J. Immunol. 2001, 167, 5386-5394.
72. Bertley, F.M.; Kozlowski, P.A.; Wang, S.W.; Chappelle, J.; Patel, J.; Sonuyi, O.; Mazzara, G.; Montefiori, D.; Carville, A.; Mansfield, K.G.; Aldovini, A. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J. Immunol. 2004, 172, 3745-3757.
73. Makitalo, B.; Lundholm, P.; Hinkula, J.; Nilsson, C.; Karlen, K.; Morner, A.; Sutter, G.; Erfle, V.; Heeney, J.L.; Wahren, B.; Biberfeld, G.; Thorstensson, R. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J. Gen. Virol. 2004, 85, 2407-2419.
74. Amara, R.R.; Villinger, F.; Altman, J.D.; Lydy, S.L.; O'Neil, S.P.; Staprans, S.I.; Montefiori, D.C.; Xu, Y.; Herndon, J.G.; Wyatt, L.S.; Candido, M.A.; Kozyr, N.L.; Earl, P.L.; Smith, J.M.; Ma, H.L.; Grimm, B.D.; Hulsey, M.L.; Miller, J.; McClure, H.M.; McNicholl, J.M.; Moss, B.; Robinson, H.L. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001, 292, 69-74.
75. Kotton, C.N.; Lankowski, A.J.; Scott, N.; Sisul, D.; Chen, L.M.; Raschke, K.; Borders, G.; Boaz, M.; Spentzou, A.; Galan, J.E.; Hohmann, E.L. Safety and immunogenicity of attenuated Salmonella enterica serovar Typhimurium delivering an HIV-1 Gag antigen via the Salmonella Type III secretion system. Vaccine 2006, 24, 6216-6224.
76. Lewis, G.K. Live-attenuated Salmonella as a prototype vaccine vector for passenger immunogens in humans: are we there yet? Expert Rev. Vaccines 2007, 6, 431-440.
77. Huang, X.; Lu, B.; Yu, W.; Fang, Q.; Liu, L.; Zhuang, K.; Shen, T.; Wang, H.; Tian, P.; Zhang, L.; Chen, Z. A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. PLoS One 2009, 4, e4180:1-e4180:9.
78. Mitchell, E.A.; Bergmeier, L.A.; Doyle, C.; Brookes, R.; Hussain, L.A.; Wang, Y.; Lehner, T. Homing of mononuclear cells from iliac lymph nodes to the genital and rectal mucosa in non-human primates. Eur. J. Immunol. 1998, 28, 3066-3074.
79. Belyakov, I.M.; Hammond, S.A.; Ahlers, J.D.; Glenn, G.M.; Berzofsky, J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J. Clin. Invest. 2004, 113, 998-1007.
80. Yu, W.; Fang, Q.; Zhu, W.; Wang, H.; Tien, P.; Zhang, L.; Chen, Z. One time intranasal vaccination with a modified vaccinia Tiantan strain MVTTZCI protects animals against pathogenic viral challenge. Vaccine 2009, doi:10.1016/j.vaccine.2009.12.038.
81. Liu, J.; O'Brien, K.L.; Lynch, D.M.; Simmons, N.L.; La Porte, A.; Riggs, A.M.; Abbink, P.; Coffey, R.T.; Grandpre, L.E.; Seaman, M.S.; Landucci, G.; Forthal, D.N.; Montefiori, D.C.; Carville, A.; Mansfield, K.G.; Havenga, M.J.; Pau, M.G.; Goudsmit, J.; Barouch, D.H. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 2009, 457, 87-91.
82. Rerks-Ngarm, S.; Pitisuttithum, P.; Nitayaphan, S.; Kaewkungwal, J.; Chiu, J.; Paris, R.; Premsri, N.; Namwat, C.; de Souza, M.; Adams, E.; Benenson, M.; Gurunathan, S.; Tartaglia, J.; McNeil, J.G.; Francis, D.P.; Stablein, D.; Birx, D.L.; Chunsuttiwat, S.; Khamboonruang, C.; Thongcharoen, P.; Robb, M.L.; Michael, N.L.; Kunasol, P.; Kim, J.H. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 2009, 361, 2209-2220.